Today, the CBO of KemPharm (NASDAQ: KMPH), Gordon K. Johnson, bought shares of KMPH for $10.45K.
This recent transaction increases Gordon K. Johnson’s holding in the company by 100% to a total of $25.5K. In addition to Gordon K. Johnson, 2 other KMPH executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, KemPharm has an average volume of 331.7K.
Starting in August 2018, KMPH received 6 Buy ratings in a row.
The insider sentiment on KemPharm has been positive according to 10 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
